CLINICAL_TRIALS
trial_result
· 2008-05-07
Clinical Trial Update: Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C [Phase 1]
Summary
A phase 1 repeat-dose study of the antibody bavituximab in patients with chronic hepatitis C has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Peregrine Pharmaceuticals | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED